Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 14/20 | 0.54 |
| ▸ | CACNA1D | Q01668 | 14/20 | 0.54 |
| ▸ | CACNA1S | Q13698 | 14/20 | 0.54 |
| ▸ | CACNA1C | Q13936 | 14/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521495 | 1.00 | CACNA1F (0.54) | CACNA1FCACNA1DCACNA1SCACNA1CATM | |
| SCHEMBL3522629 | 0.94 | CACNA1F (0.55) | CACNA1FCACNA1DCACNA1SCACNA1CATM | |
| SCHEMBL3523427 | 0.94 | CACNA1F (0.55) | CACNA1FCACNA1DCACNA1SCACNA1CATM | |
| SCHEMBL3524654 | 0.93 | ATM (0.49) | CACNA1FCACNA1DCACNA1SCACNA1CATM | |
| SCHEMBL489218 | 0.92 | CACNA1F (0.48) | CACNA1FCACNA1DCACNA1SCACNA1CATM | |
| SCHEMBL489242 | 0.91 | CACNA1F (0.53) | CACNA1FCACNA1DCACNA1SCACNA1CATM | |
| SCHEMBL3521611 | 0.90 | CACNA1F (0.54) | CACNA1FCACNA1DCACNA1SCACNA1CATM | |
| SCHEMBL3525733 | 0.90 | CACNA1F (0.54) | CACNA1FCACNA1DCACNA1SCACNA1CATM | |
| SCHEMBL13436313 | 0.87 | PPARA (0.44) | CACNA1FCACNA1DCACNA1SCACNA1CATM | |
| SCHEMBL3527673 | 0.86 | ALDH1A1 (0.48) | CACNA1FCACNA1DCACNA1SCACNA1CATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | claimed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | claimed |
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | disclosed |
| US-7687511-B2 | Substituted dihydropyrimidines, dihydropyrimidones and dihydropyrimidinethiones as calcium channel blockers | PULLELA PHANI KUMAR | 2010-03-30 | — | — | US | disclosed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | disclosed |
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | PULLELA PHANI KUMAR | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125449-A1 | SUBSTITUTED DIHYDROPYRIMIDINES, DIHYDROPYRIMIDONES AND DIHYDROPYRIMIDINETHIONES AS CALCIUM CHANNEL BLOCKERS | ORAI1, RYR2, RYR1 | CACNA1F 17/4885CACNA1D 19/4885CACNA1S 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.